Renal ImpairmentsRECAP-RxNCT07241494
Evaluation of Clinical Pharmacy Services and Drug Use in Renal Impairment.
A study testing Clinical Pharmacist-Led Pharmaceutical Care Service and Renal Dose Adjustment and Education for renal adjusments in people with Renal Impairments and Chronic Kidney Disease, run by Istanbul University - Cerrahpasa at 1 site in Turkey (Türkiye).
Trial summary
Clinical pharmacy services aim to optimise medication use, enhance patient outcomes, and reduce the risk of drug-related harm through patient-centred pharmaceutical care. In hospital settings, clinical pharmacists collaborate with physicians and other healthcare professionals as part of a multidisciplinary team to… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Renal Impairments, Chronic Kidney Disease, Acute Kidney Disease
- What is being tested?
- Clinical Pharmacist-Led Pharmaceutical Care Service and Renal Dose Adjustment and Education for renal adjusments
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 160 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 31 Oct 2021to 31 May 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Hospitalised in the General Internal Medicine ward with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m².
- Hospital stay of at least 48 hours.
- Receiving at least one medication that requires dose adjustment in renal impairment.
- Age 18 years or older.
Who cannot join
- eGFR value of 60 mL/min/1.73 m² or higher.
- Not receiving any medication that requires renal dose adjustment.
- Hospital stay shorter than 48 hours.
- Age under 18 years.
- Refusal or inability to provide informed consent.
- Lack of sufficient cognitive ability to participate in the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Investigation of Drug Use and Evaluation of Clinical Pharmacy Services in Patients With Renal Impairment.
Clinical pharmacy services aim to optimise medication use, enhance patient outcomes, and reduce the risk of drug-related harm through patient-centred pharmaceutical care. In hospital settings, clinical pharmacists collaborate with physicians and other healthcare professionals as part of a multidisciplinary team to identify, prevent, and resolve drug-related problems (DRPs). Pharmacist interventions are defined as any action initiated by a pharmacist that directly contributes to patient management or results in a modification of medication therapy. The clinical and economic benefits of such interventions have been widely recognised in various healthcare environments.
This quasi-experimental study aims to investigate the impact of clinical pharmacy services on drug use and the management of DRPs in patients with renal impairment admitted to the general internal medicine ward. The study also evaluates the contribution of the clinical pharmacist to optimising the use of drugs that require renal dose adjustment.
Read more
The study was conducted in a university hospital and included three consecutive patient groups: observation (control), education, and intervention. In the observation group, no pharmacist intervention was performed. In the education group, physicians received a structured educational presentation on renal dose adjustment for commonly prescribed medications. In the intervention group, the clinical pharmacist actively participated in daily ward rounds, identified and resolved DRPs, and provided recommendations to physicians. DRPs were classified using the Pharmaceutical Care Network Europe (PCNE) classification version 9.1.
This study evaluates whether the integration of a clinical pharmacist into the healthcare team can improve the quality of pharmacotherapy, reduce DRPs-particularly those associated with renal dysfunction-and enhance patient safety and outcomes in hospitalised patients.
Read the detailed description
Patients with renal impairment are at high risk for adverse drug reactions, medication errors, and inappropriate prescribing due to altered pharmacokinetics and pharmacodynamics. As renal function declines, dose adjustments and careful monitoring are required for many commonly prescribed drugs. Inappropriate dosing and the use of nephrotoxic agents in this population can lead to drug accumulation, toxicity, or therapeutic failure, thereby increasing the risk of hospitalisations, prolonged stays, and mortality. Previous studies have highlighted that a considerable proportion of drug-related hospital admissions are attributable to inadequate dose adjustment in patients with reduced kidney function. Therefore, careful monitoring and evidence-based dose optimisation are crucial in these patients.
Incorporating clinical pharmacy services into the care of patients with renal impairment may improve medication safety and treatment outcomes. Clinical pharmacists are well-positioned to identify and prevent drug-related problems (DRPs), recommend dose adjustments, and collaborate with physicians to enhance the quality of pharmacotherapy. Pharmacist-led interventions-such as medication reviews, dose optimisation, education of healthcare providers, and direct communication of recommendations-have been shown to reduce medication errors and improve patient outcomes in various clinical settings. Furthermore, integrating clinical pharmacists into multidisciplinary hospital teams has demonstrated positive impacts on treatment effectiveness, patient safety, and overall healthcare costs.
The present study aims to investigate drug use patterns, identify DRPs, and evaluate the impact of clinical pharmacy services on the management of patients with renal impairment admitted to the general internal medicine ward. The study specifically focuses on the pharmacist's role in optimising drug therapy for medications requiring renal dose adjustments. By assessing both the educational and interventional contributions of clinical pharmacists, this study intends to provide evidence supporting the integration of these services into routine hospital practice.
This study adopts a prospective, quasi-experimental design and was conducted in the general internal medicine ward of a university hospital. Three consecutive patient groups were included: the observation (control) group, the education group, and the intervention group. In the observation group, patients were followed without any direct pharmacist intervention. In the education group, physicians received structured training on renal dose adjustment principles and the safe use of frequently prescribed medications in renal dysfunction. In the intervention group, the clinical pharmacist actively participated in daily ward rounds, performed comprehensive medication reviews, and identified DRPs related to inappropriate drug selection, dosage errors, potential drug-drug interactions, and drugs requiring renal adjustment. The clinical pharmacist provided evidence-based recommendations to physicians regarding clinically significant findings, and these interventions were documented systematically.
All identified DRPs were classified according to the Pharmaceutical Care Network Europe (PCNE) classification system version 9.1. The clinical pharmacist's recommendations and physician acceptance rates were also recorded. Patient data-including demographic information, comorbidities, renal function parameters, prescribed medications, and relevant laboratory results-were collected prospectively. Statistical comparisons were made between the three study groups to evaluate the effect of educational and interventional phases on the frequency and nature of DRPs, particularly those associated with renal dysfunction.
Through this design, the study aims to demonstrate the stepwise impact of clinical pharmacy involvement-from passive observation to educational and active interventional roles-on the rational use of medicines in patients with renal impairment. It is expected that increased clinical pharmacist participation will lead to a reduction in DRPs, particularly those related to renal dosing errors, and improve patient outcomes by ensuring safer and more effective medication use. The findings are anticipated to contribute to the development of standardised clinical pharmacy service models and support the integration of pharmacists into multidisciplinary care teams for patients with chronic kidney disease and related comorbidities.
- Being tested
- Clinical Pharmacist-Led Pharmaceutical Care Service and Renal Dose Adjustment, Education for renal adjusments
- Keywords
- Renal impairment, drug-related problems (DRPs), clinical pharmacist, pharmaceutical care, Clinical Pharmacy Services, Medication Errors, Chronic Kidney Disease, Kidney Diseases
- Medical subject headings
- Renal Insufficiency, Chronic, Renal Insufficiency, Kidney Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical Pharmacist-Led Pharmaceutical Care Service and Renal Dose AdjustmentDrug
Also called Renal Dose Adjustment, Drug-Drug Interaction Management, Correction of Dosing Errors, Optimisation of Drug Selection
Clinical pharmacist-led interventions were implemented to optimise medication therapy and ensure patient safety among hospitalised patients with renal impairment. The interventions included several integrated pharmaceutical care activities conducted during daily ward rounds. The clinical pharmacist assessed renal function and adjusted medication doses according to up-to-date dosing guidelines and renal pharmacotherapy principles. In cases where inappropriate doses or dosing intervals were identified, corrective recommendations were communicated to the treating physicians to prevent under- or overdosing. The pharmacist also evaluated each patient's medication profile for potential drug-drug interactions and provided strategies to avoid clinically significant interactions. Drug selection was reviewed for indication, therapeutic appropriateness, and safety, with substitution or discontinuation proposed when necessary. In addition to these direct patient care activities, the clinical pharm
Education for renal adjusmentsBehavioural
The educational intervention consisted of regular training sessions delivered by the clinical pharmacist to physicians on renal dose adjustment principles, identification of nephrotoxic drugs, and prevention of drug-related problems in patients with renal impairment. The sessions aimed to improve physicians' knowledge and prescribing practices for medications requiring renal dose modification.
| Study group | Role | What they receive |
|---|---|---|
| Observation Group (Control) | No intervention | Patients with renal impairment hospitalised in the general internal medicine ward were monitored without any clinical pharmacist intervention. Prescriptions and drug use data were collected prospectively, and drug-related problems (DRPs) were identified retrospectively according to the Pharmaceutical Care Network Europe (PCNE) classification version 9.1. The results from this phase served as the baseline for comparison with subsequent groups. |
| Education Group | Active comparator | During this phase, physicians responsible for patient care received structured educational sessions delivered by the clinical pharmacist. The training focused on renal dose adjustment principles, identification of nephrotoxic drugs, and prevention of medication-related harm in patients with renal dysfunction. Patients admitted during this period were followed without direct pharmacist intervention. DRPs were identified and classified using the PCNE system to assess the indirect impact of education on prescribing behaviour. Receives: Behavioral: Education for renal adjusments |
| Intervention Group | Active comparator | In this phase, the clinical pharmacist participated actively in daily ward rounds, performed comprehensive medication reviews, and identified drug-related problems (DRPs) using the Pharmaceutical Care Network Europe (PCNE) classification version 9.1. Interventions included recommendations for renal dose adjustments, correction of dosing errors, identification and prevention of drug-drug interactions, and optimisation of drug selection. The pharmacist communicated findings and recommendations directly to the treating physicians, and acceptance of interventions was documented. Receives: Drug: Clinical Pharmacist-Led Pharmaceutical Care Service and Renal Dose Adjustment; Behavioral: Education for renal adjusments |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in the number of drug-related problems (DRPs) per patient
The total number of drug-related problems (DRPs) identified per patient, classified according to the Pharmaceutical Care Network Europe (PCNE) Classification System Version 9.1. This outcome measures the effect of clinical pharmacist-led educational and interventional activities on the identification and management of DRPs, with a specific focus on those associated with renal dysfunction.
Measured: 12 months
Secondary outcomes (2)
Percentage of drug-related problems (DRPs) associated with renal dysfunction
The percentage of total drug-related problems (DRPs) that are directly associated with renal dysfunction, including inappropriate drug selection, dosing errors, or the use of contraindicated medications. This outcome assesses the impact of clinical pharmacist-led educational and interventional activities on improving renal dose adjustment practices.
Measured: 12 months
Acceptance rate of pharmacist recommendations by physicians
The proportion of pharmacist interventions or recommendations accepted and implemented by physicians in the intervention phase. This measure assesses the feasibility, acceptance, and clinical relevance of clinical pharmacist contributions to the multidisciplinary care team.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Nov 2025
- Study start31 Oct 2021
- Primary completion31 Oct 2023
- Study completion31 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Renal ImpairmentsStudies of the same condition, open and under way.
- More trials run by Istanbul University - CerrahpasaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- This study uses a prospective, quasi-experimental design consisting of three consecutive patient groups: observation (control), education, and intervention. The groups were not randomised but were included sequentially over time in the same hospital setting. In the observation group, no clinical pharmacist intervention was provided. In the education group, physicians received structured training on renal dose adjustments for commonly prescribed medications. In the intervention group, the clinical pharmacist actively participated in daily ward rounds, identified and resolved drug-related problems (DRPs), and provided recommendations to physicians. Comparisons among the three groups were made to evaluate the effect of clinical pharmacy services and educational interventions on the identification and management of DRPs in patients with renal impairment.
- Masking
- None (open label)
- Enrolment
- 160 participants (actual)
Sponsor and investigators
- Lead sponsor
- Istanbul University - Cerrahpasa
- Sponsor type
- University, hospital or other
- Collaborators
- Bezmialem Vakif University
- Responsible party
- Principal investigator, Muhammed Yunus Bektay, Istanbul University - Cerrahpasa
- Investigators
- Muhammed Yunus BEKTAY, PHD, Principal investigator, Bezmialem Vakif University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07241494
- Sponsor's protocol ID
- 18/12
- Acronym
- RECAP-Rx
- Status last verified
- Nov 2025
- First submitted
- 17 Nov 2025
- Last updated
- 1 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The IPD will not be shared due to ethical necessities.
Study at a glance
From the registry record, last updated by the sponsor on 1 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of Drug Use and Evaluation of Clinical Pharmacy Services in Patients With Renal Impairment.
- ClinicalTrials.gov ID
- NCT07241494
- Acronym / sponsor ID
- RECAP-Rx / 18/12
- Keywords
- Renal impairment, drug-related problems (DRPs), clinical pharmacist, pharmaceutical care, Clinical Pharmacy Services, Medication Errors, Chronic Kidney Disease, Kidney Diseases
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 160 participants (actual)
- Lead sponsor
- Istanbul University - CerrahpasaUniversity, hospital or other
- Collaborators
- Bezmialem Vakif University
- Study start
- 31 Oct 2021 (actual)
- Primary completion
- 31 Oct 2023 (actual)
- Study completion
- 31 May 2024 (actual)
- First posted
- 21 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Clinical pharmacy services aim to optimise medication use, enhance patient outcomes, and reduce the risk of drug-related harm through patient-centred pharmaceutical care. In hospital settings, clinical pharmacists collaborate with physicians and other healthcare professionals as part of a multidisciplinary team to identify, prevent, and resolve drug-related problems (DRPs). Pharmacist interventions are defined as any action initiated by a pharmacist that directly contributes to patient management or results in a modification of medication therapy. The clinical and economic benefits of such interventions have been widely recognised in various healthcare environments.
This quasi-experimental study aims to investigate the impact of clinical pharmacy services on drug use and the management of DRPs in patients with renal impairment admitted to the general internal medicine ward. The study also evaluates the contribution of the clinical pharmacist to optimising the use of drugs that require renal dose adjustment.
The study was conducted in a university hospital and included three consecutive patient groups: observation (control), education, and intervention. In the observation group, no pharmacist intervention was performed. In the education group, physicians received a structured educational presentation on renal dose adjustment for commonly prescribed medications. In the intervention group, the clinical pharmacist actively participated in daily ward rounds, identified and resolved DRPs, and provided recommendations to physicians. DRPs were classified using the Pharmaceutical Care Network Europe (PCNE) classification version 9.1.
This study evaluates whether the integration of a clinical pharmacist into the healthcare team can improve the quality of pharmacotherapy, reduce DRPs-particularly those associated with renal dysfunction-and enhance patient safety and outcomes in hospitalised patients.
Detailed description
Patients with renal impairment are at high risk for adverse drug reactions, medication errors, and inappropriate prescribing due to altered pharmacokinetics and pharmacodynamics. As renal function declines, dose adjustments and careful monitoring are required for many commonly prescribed drugs. Inappropriate dosing and the use of nephrotoxic agents in this population can lead to drug accumulation, toxicity, or therapeutic failure, thereby increasing the risk of hospitalisations, prolonged stays, and mortality. Previous studies have highlighted that a considerable proportion of drug-related hospital admissions are attributable to inadequate dose adjustment in patients with reduced kidney function. Therefore, careful monitoring and evidence-based dose optimisation are crucial in these patients.
Incorporating clinical pharmacy services into the care of patients with renal impairment may improve medication safety and treatment outcomes. Clinical pharmacists are well-positioned to identify and prevent drug-related problems (DRPs), recommend dose adjustments, and collaborate with physicians to enhance the quality of pharmacotherapy. Pharmacist-led interventions-such as medication reviews, dose optimisation, education of healthcare providers, and direct communication of recommendations-have been shown to reduce medication errors and improve patient outcomes in various clinical settings. Furthermore, integrating clinical pharmacists into multidisciplinary hospital teams has demonstrated positive impacts on treatment effectiveness, patient safety, and overall healthcare costs.
The present study aims to investigate drug use patterns, identify DRPs, and evaluate the impact of clinical pharmacy services on the management of patients with renal impairment admitted to the general internal medicine ward. The study specifically focuses on the pharmacist's role in optimising drug therapy for medications requiring renal dose adjustments. By assessing both the educational and interventional contributions of clinical pharmacists, this study intends to provide evidence supporting the integration of these services into routine hospital practice.
This study adopts a prospective, quasi-experimental design and was conducted in the general internal medicine ward of a university hospital. Three consecutive patient groups were included: the observation (control) group, the education group, and the intervention group. In the observation group, patients were followed without any direct pharmacist intervention. In the education group, physicians received structured training on renal dose adjustment principles and the safe use of frequently prescribed medications in renal dysfunction. In the intervention group, the clinical pharmacist actively participated in daily ward rounds, performed comprehensive medication reviews, and identified DRPs related to inappropriate drug selection, dosage errors, potential drug-drug interactions, and drugs requiring renal adjustment. The clinical pharmacist provided evidence-based recommendations to physicians regarding clinically significant findings, and these interventions were documented systematically.
All identified DRPs were classified according to the Pharmaceutical Care Network Europe (PCNE) classification system version 9.1. The clinical pharmacist's recommendations and physician acceptance rates were also recorded. Patient data-including demographic information, comorbidities, renal function parameters, prescribed medications, and relevant laboratory results-were collected prospectively. Statistical comparisons were made between the three study groups to evaluate the effect of educational and interventional phases on the frequency and nature of DRPs, particularly those associated with renal dysfunction.
Through this design, the study aims to demonstrate the stepwise impact of clinical pharmacy involvement-from passive observation to educational and active interventional roles-on the rational use of medicines in patients with renal impairment. It is expected that increased clinical pharmacist participation will lead to a reduction in DRPs, particularly those related to renal dosing errors, and improve patient outcomes by ensuring safer and more effective medication use. The findings are anticipated to contribute to the development of standardised clinical pharmacy service models and support the integration of pharmacists into multidisciplinary care teams for patients with chronic kidney disease and related comorbidities.
Study design
- Primary purpose
- Health services research
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- This study uses a prospective, quasi-experimental design consisting of three consecutive patient groups: observation (control), education, and intervention. The groups were not randomised but were included sequentially over time in the same hospital setting. In the observation group, no clinical pharmacist intervention was provided. In the education group, physicians received structured training on renal dose adjustments for commonly prescribed medications. In the intervention group, the clinical pharmacist actively participated in daily ward rounds, identified and resolved drug-related problems (DRPs), and provided recommendations to physicians. Comparisons among the three groups were made to evaluate the effect of clinical pharmacy services and educational interventions on the identification and management of DRPs in patients with renal impairment.
| Arm | Type | Receives |
|---|---|---|
| Observation Group (Control) | No intervention | –Patients with renal impairment hospitalised in the general internal medicine ward were monitored without any clinical pharmacist intervention. Prescriptions and drug use data were collected prospectively, and drug-related problems (DRPs) were identified retrospectively according to the Pharmaceutical Care Network Europe (PCNE) classification version 9.1. The results from this phase served as the baseline for comparison with subsequent groups. |
| Education Group | Active comparator | Behavioral: Education for renal adjusmentsDuring this phase, physicians responsible for patient care received structured educational sessions delivered by the clinical pharmacist. The training focused on renal dose adjustment principles, identification of nephrotoxic drugs, and prevention of medication-related harm in patients with renal dysfunction. Patients admitted during this period were followed without direct pharmacist intervention. DRPs were identified and classified using the PCNE system to assess the indirect impact of education on prescribing behaviour. |
| Intervention Group | Active comparator | Drug: Clinical Pharmacist-Led Pharmaceutical Care Service and Renal Dose Adjustment, Behavioral: Education for renal adjusmentsIn this phase, the clinical pharmacist participated actively in daily ward rounds, performed comprehensive medication reviews, and identified drug-related problems (DRPs) using the Pharmaceutical Care Network Europe (PCNE) classification version 9.1. Interventions included recommendations for renal dose adjustments, correction of dosing errors, identification and prevention of drug-drug interactions, and optimisation of drug selection. The pharmacist communicated findings and recommendations directly to the treating physicians, and acceptance of interventions was documented. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Hospitalised in the General Internal Medicine ward with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m².
- Hospital stay of at least 48 hours.
- Receiving at least one medication that requires dose adjustment in renal impairment.
- Age 18 years or older.
Key exclusion criteria (6 listed)
- eGFR value of 60 mL/min/1.73 m² or higher.
- Not receiving any medication that requires renal dose adjustment.
- Hospital stay shorter than 48 hours.
- Age under 18 years.
- Refusal or inability to provide informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical Pharmacist-Led Pharmaceutical Care Service and Renal Dose AdjustmentAlso: Renal Dose Adjustment, Drug-Drug Interaction Management, Correction of Dosing Errors, Optimisation of Drug SelectionClinical pharmacist-led interventions were implemented to optimise medication therapy and ensure patient safety among hospitalised patients with renal impairment. The interventions included several integrated pharmaceutical care activities conducted during daily ward rounds. The clinical pharmacist assessed renal function and adjusted medication doses according to up-to-date dosing guidelines and renal pharmacotherapy principles. In cases where inappropriate doses or dosing intervals were identified, corrective recommendations were communicated to the treating physicians to prevent under- or overdosing. The pharmacist also evaluated each patient's medication profile for potential drug-drug interactions and provided strategies to avoid clinically significant interactions. Drug selection was reviewed for indication, therapeutic appropriateness, and safety, with substitution or discontinuation proposed when necessary. In addition to these direct patient care activities, the clinical pharm | Drug | Intervention Group |
| Education for renal adjusmentsThe educational intervention consisted of regular training sessions delivered by the clinical pharmacist to physicians on renal dose adjustment principles, identification of nephrotoxic drugs, and prevention of drug-related problems in patients with renal impairment. The sessions aimed to improve physicians' knowledge and prescribing practices for medications requiring renal dose modification. | Behavioural | Education Group, Intervention Group |
Primary outcome
Change in the number of drug-related problems (DRPs) per patient
Time frame: 12 months
The total number of drug-related problems (DRPs) identified per patient, classified according to the Pharmaceutical Care Network Europe (PCNE) Classification System Version 9.1. This outcome measures the effect of clinical pharmacist-led educational and interventional activities on the identification and management of DRPs, with a specific focus on those associated with renal dysfunction.
2 secondary outcomes
Percentage of drug-related problems (DRPs) associated with renal dysfunction
Time frame: 12 months
Acceptance rate of pharmacist recommendations by physicians
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Dec 2025.
- Individual participant dataSharing planned: No. The IPD will not be shared due to ethical necessities.
Related trials for Renal Impairments
Not yet recruitingPhase 1
A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013)
Healthy, Renal Impairment
Not yet recruitingPhase 1
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia
RecruitingPhase 1
A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal Function
Participants With Moderate and Severe Renal Impairment and Healthy Participants
RecruitingPhase 4
Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment
Ureter Injury
RecruitingObservational study
Physical Impairments in Children With Chronic Renal Failure
Chronic Kidney Failure, Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Muhammed Yunus BEKTAY, PHD principal investigator
Bezmialem Vakif University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clinical Pharmacist-Led Pharmaceutical Care Service and Renal Dose Adjustment and Education for renal adjusments in people with Renal Impairments and Chronic Kidney Disease, run by Istanbul University - Cerrahpasa at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in the number of drug-related problems (DRPs) per patient (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Dec 2025.